肺腺癌的放射抵抗：机制、靶点与逆转策略研究进展
Radiation Resistance in Lung Adenocarcinoma: Mechanisms, Therapeutic Targets, and Reversal Strategies—A Review of Recent Advances
DOI: 10.12677/jcpm.2026.51053, PDF,   
作者: 陈逸轩：华北理工大学附属医院放化疗四科，河北 唐山；孙国贵：华北理工大学附属医院放化疗二科，河北 唐山
关键词: 肺腺癌；放射抵抗；信号通路；联合治疗；LUAD； Radioresistance； Signaling Pathway； Combination Therapy
摘要: 肺腺癌(LUAD)是非小细胞肺癌(NSCLC)最主要的病理亚型，尽管放疗(RT)仍是LUAD治疗的基石，但LUAD具有高度的放射抗性，这显著限制了治疗效果并影响预后。本文系统综述近15年国内外研究进展，聚焦线粒体代谢重编程、肿瘤微环境与自噬调控系统、表观遗传修饰及信号通路紊乱四大核心机制，并总结靶向肿瘤微环境、表观遗传调节剂及联合治疗等逆转策略的研究现状。结合最新临床前与临床证据，展望多靶点协同治疗及个体化放疗方案的发展方向，为克服肺腺癌放射抵抗提供理论依据与转化思路。
Abstract: Lung adenocarcinoma (LUAD) is the most predominant pathological subtype of non-small cell lung cancer (NSCLC). Although radiotherapy (RT) remains the cornerstone of LUAD treatment, LUAD exhibits high radioresistance, which significantly limits therapeutic efficacy and impacts prognosis. This review systematically summarizes the research advances at home and abroad over the past 15 years, focusing on four core mechanisms: mitochondrial metabolic reprogramming, the tumor microenvironment (TME) and autophagic regulatory system, epigenetic modifications, and dysregulated signaling pathways. Additionally, it summarizes the current research status of reversal strategies, including targeting the tumor microenvironment, epigenetic modulators, and combination therapy. Combined with the latest preclinical and clinical evidence, this review outlines the development direction of multi-target synergistic therapy and personalized radiotherapy regimens, providing a theoretical basis and translational insights for overcoming radioresistance in LUAD.
文章引用：陈逸轩, 孙国贵. 肺腺癌的放射抵抗：机制、靶点与逆转策略研究进展[J]. 临床个性化医学, 2026, 5(1): 379-383. https://doi.org/10.12677/jcpm.2026.51053

参考文献

[1] Cong, L., Yi, J., Qiu, S., Wang, R., Jin, S., Jiang, R., et al. (2021) Effect of EG00229 on Radiation Resistance of Lung Adenocarcinoma Cells. Journal of Cancer, 12, 6105-6117. [Google Scholar] [CrossRef] [PubMed]
[2] 宋帅, 赫丽杰, 韩彧佳, 等. 非小细胞肺癌放疗抵抗研究进展[J]. 现代肿瘤医学, 2019, 27(19): 3520-3523.
[3] Averbeck, D. and Rodriguez-Lafrasse, C. (2021) Role of Mitochondria in Radiation Responses: Epigenetic, Metabolic, and Signaling Impacts. International Journal of Molecular Sciences, 22, Article No. 11047. [Google Scholar] [CrossRef] [PubMed]
[4] Sancho, P., Burgos-Ramos, E., Tavera, A., Bou Kheir, T., Jagust, P., Schoenhals, M., et al. (2015) MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. Cell Metabolism, 22, 590-605. [Google Scholar] [CrossRef] [PubMed]
[5] Liu, Y., Shi, Q., Ye, Y., Tashiro, S., Onodera, S. and Ikejima, T. (2012) Activated O− 2 and H2O2 Mediated Cell Survival in SU11274-Treated Non-Small-Cell Lung Cancer A549. Journal of Pharmacological Sciences, 119, 150-159. [Google Scholar] [CrossRef] [PubMed]
[6] Lee, J.M., Kim, H.S., Kim, A., Chang, Y.S., Lee, J.G., Cho, J., et al. (2022) ABT-737, a BH3 Mimetic, Enhances the Therapeutic Effects of Ionizing Radiation in K-Ras Mutant Non-Small Cell Lung Cancer Preclinical Model. Yonsei Medical Journal, 63, 16-25. [Google Scholar] [CrossRef] [PubMed]
[7] Xiang, K., Jendrossek, V. and Matschke, J. (2020) Oncometabolites and the Response to Radiotherapy. Radiation Oncology, 15, Article No. 197. [Google Scholar] [CrossRef] [PubMed]
[8] Gong, C., Li, W., Wu, J., Li, Y., Ma, Y. and Tang, L. (2022) AKBA Inhibits Radiotherapy Resistance in Lung Cancer by Inhibiting Maspin Methylation and Regulating the AKT/FOXO1/p21 Axis. Journal of Radiation Research, 64, 33-43. [Google Scholar] [CrossRef] [PubMed]
[9] Kozłowska-Masłoń, J., Guglas, K., Paszkowska, A., Kolenda, T., Podralska, M., Teresiak, A., et al. (2022) Radio-lncRNAs: Biological Function and Potential Use as Biomarkers for Personalized Oncology. Journal of Personalized Medicine, 12, Article No. 1605. [Google Scholar] [CrossRef] [PubMed]
[10] Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., et al. (2006) Glioma Stem Cells Promote Radioresistance by Preferential Activation of the DNA Damage Response. Nature, 444, 756-760. [Google Scholar] [CrossRef] [PubMed]
[11] Ji, N., Li, S., Shao, L., Li, Q., Xu, J. and Zeng, Y. (2025) MDMX Enhances Radiosensitivity in Lung Adenocarcinoma and Squamous Cell Carcinoma by Inhibiting P53-Mediated Autophagy. Cellular Oncology, 48, 1067-1088. [Google Scholar] [CrossRef] [PubMed]
[12] Wang, Y., Shang, Y., Hua, M., Wang, Y., Hui, B., Hu, W., et al. (2025) Identification and Exploration of Key Genes Associated with Radioresistance in Lung Adenocarcinoma. Cancer Cell International, 25, Article No. 155. [Google Scholar] [CrossRef] [PubMed]
[13] Liang, S., Zhou, G. and Hu, W. (2022) Research Progress of Heavy Ion Radiotherapy for Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences, 23, Article No. 2316. [Google Scholar] [CrossRef] [PubMed]
[14] Oroz-Parra, I., Navarro, M., Cervantes-Luevano, K., Álvarez-Delgado, C., Salvesen, G., Sanchez-Campos, L., et al. (2016) Apoptosis Activation in Human Lung Cancer Cell Lines by a Novel Synthetic Peptide Derived from Conus Californicus Venom. Toxins, 8, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[15] Moro, S., Omrani, M., Erbek, S., Jourdan, M., Vandekerckhove, C.I., Nogier, C., et al. (2024) Self‐Assembled Peptide‐Gold Nanoclusters with SiRNA Targeting Telomeric Response to Enhance Radiosensitivity in Lung Cancer Cells. Small Science, 5, Article ID: 2400156. [Google Scholar] [CrossRef] [PubMed]
[16] Li, S., Feng, J., Weng, H., Zhao, F., Cui, G., Fu, W., et al. (2022) Identification of Key Genes and Functional Pathway in Radioresistance of Non-Small Cell Lung Cancer. Cancer Management and Research, 14, 2871-2884. [Google Scholar] [CrossRef] [PubMed]
[17] Fotin-Mleczek, M., Zanzinger, K., Heidenreich, R., Lorenz, C., Kowalczyk, A., Kallen, K., et al. (2014) mRNA-Based Vaccines Synergize with Radiation Therapy to Eradicate Established Tumors. Radiation Oncology, 9, Article No. 180. [Google Scholar] [CrossRef] [PubMed]
[18] Malekghasemi, S., Majidi, J., Baghbanzadeh, A., Abdolalizadeh, J., Baradaran, B. and Aghebati-Maleki, L. (2020) Tumor-Associated Macrophages: Protumoral Macrophages in Inflammatory Tumor Microenvironment. Advanced Pharmaceutical Bulletin, 10, 556-565. [Google Scholar] [CrossRef] [PubMed]
[19] Xu, T., Fang, Y., Gu, Y., Xu, D., Hu, T., Yu, T., et al. (2024) HDAC Inhibitor SAHA Enhances Antitumor Immunity via the HDAC1/JAK1/FGL1 Axis in Lung Adenocarcinoma. Journal for ImmunoTherapy of Cancer, 12, e010077. [Google Scholar] [CrossRef] [PubMed]